By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Friedrich-Ebert-Str. 475
Building 302
Wuppertal    D-42117  Germany
Phone: 49-0-202-31763-0 Fax: 49-0-202-31763-1177



Company News
AiCuris Initiates U.S. Clinical Phase II Trial With Oral Pritelivir For The Treatment Of HSV Infections In Immunocompromised Adults 5/9/2017 7:57:25 AM
AiCuris Release: Pharma Announces Publication Of Phase 2 Clinical Trial Results Of Investigational Anti-Herpes Simplex Virus Agent Pritelivir In JAMA 1/17/2017 11:54:56 AM
AiCuris Announces U.S. NIH Support Of Preclinical Study With AIC649 Against Chronic Hepatitis B 11/23/2016 1:52:44 PM
AiCuris Initiates Clinical Development For Topical Pritelivir, A Highly Active Inhibitor For The Treatment Of Herpes Simplex Virus 4/4/2016 9:00:45 AM
AiCuris' AIC649 Shows Potential To Induce Functional Cure Of Chronic Hepatitis B In Preclinical Study 1/5/2016 10:18:48 AM
AiCuris Strengthens Its Management 6/3/2015 9:40:09 AM
AiCuris And Merck & Co., Inc. (MRK) Announce Publication In New England Journal Of Medicine Of Phase 2 Clinical Trial Results Of Investigational Antiviral Agent Letermovir In Bone Marrow Transplant Patients 5/8/2014 10:54:18 AM
AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir 1/29/2013 10:55:50 AM
Merck & Co., Inc. (MRK), AiCuris Ink $571 Million CMV Pact 10/30/2012 1:02:13 PM
AiCuris Promising Drugs Against Herpes Simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in Preparation for Phase III 8/7/2012 10:39:46 AM